Mining for a diagnosis of Wilson's disease in children: Genetics, score, and ore
Richard A. Rosencrantz, Michael L. Schilsky – 26 October 2010
Hepatitis C pharmacogenetics: State of the art in 2010
Nezam H. Afdhal, John G. McHutchison, Stefan Zeuzem, Alessandra Mangia, Jean‐Michel Pawlotsky, Jeffrey S. Murray, Kevin V. Shianna, Yasuhito Tanaka, David L. Thomas, David R. Booth, David B. Goldstein, for the Pharmacogenetics and Hepatitis C Meeting Participants – 26 October 2010 – In 2009, a correlated set of polymorphisms in the region of the interleukin‐28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon‐alfa and ribavirin.
Beta‐blockers have no effect on outcomes in patients with cirrhosis and severe infections
Arnaud Galbois, Vincent Das, Dominique Thabut, Eric Maury, Hafid Ait‐Oufella, Chantal Housset, Bertrand Guidet – 26 October 2010
Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites
Mevlut Kurt – 26 October 2010
Reply:
Tahany Awad, Kristian Thorlund, Goran Hauser, Davor Stimac, Mahasen Mabrouk, Christian Gluud – 26 October 2010
Pharmacokinetics for once‐daily versus twice‐daily tacrolimus formulations in de novo liver transplantation: A randomized, open‐label trial
Lutz Fischer, Pavel Trunečka, Bruno Gridelli, Andre Roy, Alessandro Vitale, Andrés Valdivieso, Evaristo Varo, Daniel Seehofer, Stephen Lynch, Didier Samuel, Bo‐Goran Ericzon, Karim Boudjema, Carmen Karpf, Nasrullah Undre – 21 October 2010 – Tacrolimus, a cornerstone immunosuppressant, is available as a twice‐daily formulation (tacrolimus bid). A once‐daily prolonged‐release formulation (tacrolimus qd) has been developed.
Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct–ligated rats and human hepatic cells
Hongwei He, Albert Mennone, James L. Boyer, Shi‐Ying Cai – 21 October 2010 – Cholestasis leads to liver cell death, fibrosis, cirrhosis, and eventually liver failure. Despite limited benefits, ursodeoxycholic acid (UDCA) is the only Food and Drug Administration–approved treatment for cholestatic disorders. Retinoic acid (RA) is a ligand for nuclear receptors that modulate bile salt homeostasis. RA also possesses immunomodulatory effects and is used to treat acute promyelocytic leukemia and inflammatory disorders such as psoriasis, acne, and rheumatoid arthritis.
Domino versus deceased donor liver transplantation: Association with early graft function and perioperative bleeding
Miguel Bispo, Paulo Marcelino, Hugo Pinto Marques, Américo Martins, Rui Perdigoto, Maria João Aguiar, Luís Mourão, Eduardo Barroso – 21 October 2010 – This study sought to evaluate the potential impact of domino liver transplantation (DLT) on initial graft function and early postoperative outcome in patients with cirrhosis in a Portuguese liver transplantation center.
Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C Virus 1 year after liver transplantation
Pinelopi Manousou, Amar P. Dhillon, Graziela Isgro, Vincenza Calvaruso, T.V. Luong, Emmanuel Tsochatzis, E. Xirouchakis, G. Kalambokis, Timothy J. Cross, N. Rolando, James O'Beirne, David Patch, D. Thornburn, Andrew K. Burroughs – 21 October 2010 – Clinical outcomes of recurrent hepatitis C virus after liver transplantation are difficult to predict. We evaluated collagen proportionate area (CPA), a quantitative histological index, at 1 year with respect to the first episode of clinical decompensation.